JDJean-Guillaume Dillinger

Jean-Guillaume Dillinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean-Guillaume Dillinger has a total of 329 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick Henry

    Université Paris Cité, Service de Cardiologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Inserm MASCOT-UMRS 942, University Hospital of Lariboisiere, Paris, France

    15 shared publications
  • Patrick Henry

    CHU Lariboisière, Departement de Cardiologie, Paris, France

    15 shared publications
  • Claire Bal Dit Sollier

    CREATIF, Centre de Référence et d'Education des antithrombotiques d'Ile de France, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    11 shared publications
  • Georgios Sideris

    CHU Lariboisière, Departement de Cardiologie, Paris, France

    11 shared publications
  • Sebastian Voicu

    11 shared publications
  • Théo Pezel

    Hôpital Lariboisière, (Assistance Publique des Hôpitaux de Paris, AP-HP), Cardiology department, Université Paris Cité , Paris

    10 shared publications

Latest Publications

  • Open Access

    Machine learning for 5-year mortality prediction in hospital survivors of STEMI undergoing coronary angiography: insights from the FAST-MI registries

    by Manveer Singh, Emmanuel Gall, Kenza Hamzi, Solenn Toupin, Trecy Gonçalves, Jean Guillaume Dillinger, Patrick Henry, Charles Fauvel, Antonin Trimaille, Néfissa Hammache, et al.

    Background: Machine learning (ML) may enhance the predictive performance of traditional risk models after myocardial infarction (MI). This study aimed to develop and validate an ML-based model to predict 5-year all-cause mortality after hospital discharge in patients with ST-elevation myocardial infarction (STEMI). Methods: Data were obtained from the FAST-MI 2010 and 2015 multicenter, prospective registries. A total of 4,754 STEMI patients who underwent coronary angiography and survived to hospital discharge were included and randomly split into a training cohort (3,334 patients) and a validation cohort (1,420 patients). The primary endpoint was 5-year all-cause mortality. Among 34 candidate variables, the Boruta algorithm identified the most relevant predictors, including age, hemoglobin, creatinine, left ventricular ejection fraction, Killip class, and histories of stroke, heart failure, peripheral artery disease, cancer, and atrial fibrillation. Three ML classifiers—extreme gradient boosting (XGB), random forest, and support vector machine—were compared with logistic regression (LR). Results: During 5-year follow-up, 555 deaths (11.7%) occurred. XGB showed the best performance among ML methods and was selected as the final model. In the validation cohort, the ML model achieved an AUROC of 0.81 [95% CI 0.77–0.85], which was comparable to that of LR (0.80 [95% CI 0.77–0.84]; DeLong’s test p=0.79). The corresponding PRAUC values were 0.45 [95% CI 0.37–0.53] and 0.42 [95% CI 0.34–0.49], respectively. The ML model demonstrated improved calibration, particularly in low-risk patients. Conclusions: Among hospital survivors of STEMI who underwent coronary angiography, ML did not substantially improve 5-year mortality prediction compared with LR based on routinely available clinical variables.Keywords: Myocardial Infarction; ST Elevation Myocardial Infarction; Machine Learning; Mortality; Risk Assessment

  • Stress CMR ischaemic burden and long-term mortality in left ventricular systolic dysfunction: a multicentre registry study

    by Alexandre Pfeffer, JérÔme Garot, Suzanne Duhamel, Philippe Garot, Francesca Sanguineti, Thomas Hovasse, StépHane Champagne, Thierry Unterseeh, Mariama Akodad, Antoinette Neylon, et al.

    Aims: Stress perfusion cardiovascular magnetic resonance (CMR) integrates the assessment of myocardial ischaemia, scar, and function. Its incremental prognostic value in patients with left ventricular (LV) systolic dysfunction remains uncertain. Methods and results: We analysed a prospective multicentre registry of consecutive patients undergoing vasodilator stress perfusion CMR at three French centres (2008–24). Patients with CMR-derived LVEF < 50% were included. The primary end point was all-cause mortality. Associations were estimated with multivariable Cox models. Incremental prognostic value of ischaemia and late gadolinium enhancement (LGE) beyond clinical factors and LVEF was assessed by likelihood ratio χ2, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Among 5977 patients (79% men; age 66 ± 12 years, mean LVEF 42 ± 7%), inducible ischaemia was present in 19% (mean extent 2.4 ± 1.2 segments). Over a median follow-up of 9 years, 1343 patients (22%) died. Ischaemic segment extent was independently associated with mortality (HR per segment 1.11; 95% CI, 1.06–1.15; P < 0.001). Adding ischaemia and LGE to clinical factors and LVEF improved model fit and reclassification (global χ2 increased from 707 to 728; NRI 0.217; IDI 0.004; all P < 0.001). Findings were consistent across LVEF subgroups (40–50% and <40%). In secondary analyses among patients with ischaemia, outcomes differed by subsequent revascularization status; these findings are observational and hypothesis-generating. Conclusion: In patients with LVEF < 50%, ischaemic burden on stress CMR is independently associated with long-term mortality beyond clinical factors, LVEF and LGE. Integrating ischaemia and scar metrics provides incremental prognostic information that may aid risk stratification using stress CMR in LV systolic dysfunction.

  • Concomitant hypertension in hypertrophic cardiomyopathy: clinical phenotype and prognostic associations of cardiovascular magnetic resonance biomarkers

    by Jeremy Florence, Trecy GonçaLves, Solenn Toupin, Suzanne Duhamel, Philippe Garot, Julien Hudelo, Francesca Sanguineti, Thomas Hovasse, Mariama Akodad, Antoinette Neylon, et al.

    Aims: To characterize the cardiovascular magnetic resonance (CMR) phenotype of hypertensive hypertrophic cardiomyopathy (HCM) patients, assess the association between hypertension and all-cause mortality, and compare the long-term prognostic performance of CMR-derived biomarkers between hypertensive and non-hypertensive HCM patients. Methods and results: Between 2008 and 2024, all consecutive HCM patients referred for CMR from the hypertrophic cardiomyopathy-late gadolinium enhancement registry were included. The primary outcome was all-cause mortality. Clinical variables, cardiac volumes, myocardial mass, functions, and tissue characterization with late gadolinium enhancement (LGE) were assessed in all patients. The prognostic value of hypertension and CMR-derived biomarkers were assessed using survival analysis. Among 2873 patients with HCM (52 ± 8 years, 56% males), 796 (28%) had hypertension. Hypertensive HCM patients had greater LGE extent (1.1 ± 1.8 vs. 0.9 ± 1.5, P < 0.001), more LGE multiple locations (17% vs. 11%, P < 0.001), and more midwall LGE (35% vs. 28%, P = 0.001). After 1:1 propensity score matching, survival curves showed an increased risk of all-cause mortality for hypertensive HCM patients over a median follow-up of 9 years [hazard ratio (HR): 1.32, 95% confidence interval (CI): 1.04–1.69; log-rank P = 0.024]. High LGE extent (more than three segments) and septal location of LGE were independently associated with mortality in both hypertensive HCM patients (HR: 3.99, 95% CI: 2.21–7.18; P < 0.001 and HR: 1.76, 95% CI: 1.03–3.01; P = 0.039, respectively) and non-hypertensive HCM patients (HR: 4.63, 95% CI: 2.15–9.97; P < 0.001 and HR: 1.48, 95% CI: 1.02–2.15; P = 0.040, respectively). Conclusion: In a large multicenter cohort of HCM patients, concomitant hypertension was associated with increased long-term mortality, and prognostic associations of CMR-LGE biomarkers were found. These findings highlight the importance of comprehensive cardiovascular risk assessment in HCM patients.

  • Long-term Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients with Hypertension without known coronary artery disease

    by Sonia Houssany-Pissot, Jérôme Garot, Suzanne Duhamel, Solenn Toupin, Alexandre Unger, Francesca Sanguineti, Stéphane Champagne, Thierry Unterseeh, Bernard Chevalier, Jeremy Florence, et al.

    AIM: Benefits of screening coronary artery disease (CAD) using stress perfusion cardiovascular magnetic resonance (CMR) in patients with hypertension without known CAD is not well established. The aim of our study was to assess the long-term prognostic value of vasodilator stress CMR in patients with hypertension without known CAD. METHODS: Between December 2008 and January 2022, all consecutive patients with hypertension without known CAD referred for stress CMR were followed up to the occurrence of major cardiovascular events (MACE), defined as cardiovascular mortality or non-fatal myocardial infarction (MI). Cox regressions were performed to determine the prognostic value of each parameter. RESULTS: Among 2,019 patients (69 ± 12 years; 45% male) with a median follow up of 6.7 (5.9- 8.9) years, 327 had MACE (16%). Patients without ischaemia experienced a lower rate of MACE than those with ischaemia (12 versus 39%, respectively, p < 0.001). Ischaemia and unrecognised MI were both significantly associated with the occurrence of MACE (respectively, HR: 4.1, 99.5%CI: 3.0-5.7 and HR: 3.6, 99.5%CI: 2.6-5.1, both p < 0.001). After adjustment, both the extent of ischaemia and unrecognised MI were independent predictors of MACE (respectively, HR: 1.2, 99.5%CI: 1.2-1.3, and HR: 1.2, 99.5%CI: 1.1-1.3, both p < 0.001). Adding stress CMR parameters improved model discrimination and reclassification, with greatest improvements in stepwise Model (C-statistic improvement: 0.02; net reclassification improvement: 0.50; integrative discrimination index: 0.02; all p < 0.001). CONCLUSION: In patients with hypertension without known CAD, stress CMR is a long-term predictor for the incidence of MACE and offer an incremental prognostic value over traditional predictors.

  • Prognostic Impact of LGE Granularity Using CMR in End‑Stage Hypertrophic Cardiomyopathy

    by Julien Hudelo, Jérôme Garot, Solenn Toupin, Suzanne Duhamel, Francesca Sanguineti, Philippe Garot, Thomas Hovasse, Stéphane Champagne, Thierry Unterseeh, Mariama Akodad, et al.

    BACKGROUND: End-stage hypertrophic cardiomyopathy (HCM) is a distinct and advanced form of HCM, defined by a left ventricular ejection fraction P =0.02). Each LGE granularity component was independently associated with mortality after adjustment: LGE extent (hazard ratio, 2.85 [95% CI, 1.03–7.85]; P =0.02), septal location (hazard ratio, 1.73 [95% CI, 1.10–2.73]; P P <0.001). CONCLUSIONS: In this large multicenter cohort of patients with end-stage HCM, the LGE granularity model integrating LGE extent, location, and pattern provided strong and independent prognostic value.


  • Stress Perfusion CMR Imaging-Guided Management and Prognosis in Patients With Suspected Coronary Heart Disease

    by Antonin Trimaille, Philippe Garot, Solenn Toupin, Francesca Sanguineti, Thomas Hovasse, Suzanne Duhamel, StépHane Champagne, Thierry Unterseeh, Mariama Akodad, Antoinette Neylon, et al.

    BACKGROUND: Identifying patients with chronic coronary syndrome who will benefit most from a coronary revascularization strategy is essential. Data on the performance of stress cardiac magnetic resonance (CMR) to guide revascularization are limited. To assess the long-term prognostic impact of stress CMR-guided revascularization strategy to predict all-cause death. METHODS: We conducted an observational study including all consecutive patients who underwent stress CMR for suspected or known chronic coronary syndrome in 3 centers in France. CMR-guided coronary revascularization was defined as any revascularization performed within 90 days following stress CMR. The primary outcome was all-cause death. RESULTS: A total of 50 701 patients were included (mean age, 64±12 years; 68.5% men). After a median follow-up of 7.2 years (interquartile range, 3.0–11.0), 3665 (7.2%) patients died. Among the 7396 patients with ischemia, 6523 (88%) underwent revascularization. Ischemia and late gadolinium enhancement (LGE) without viability were independent predictors of death (adjusted hazard ratio, 3.67 [99.5% CI, 3.15–4.27] and adjusted hazard ratio, 1.26 [99.5% CI, 1.10–1.44], respectively; P P P P =0.23). CONCLUSIONS: In this registry of consecutive patients with chronic coronary syndrome from 3 centers, stress CMR-guided revascularization was associated with a lower rate of death. The combined assessment of inducible myocardial ischemia and LGE may help to select patients most suitable for revascularization.


  • Association Between Recreational Drug Use and Cardiovascular Events Post-Hospitalization in France

    by Raphael Mirailles, Clément Delmas, Solenn Toupin, Claire Bouleti, Antonin Trimaille, Guillaume Schurtz, Nicolas Piliero, Stéphane Andrieu, Benoît Lattuca, Reza Rossanaly Vasram, et al.

    BACKGROUND: Although recent work has shown that recent recreational drug use is associated with in-hospital outcomes in patients admitted to the intensive cardiac care unit (ICCU), its cardiovascular consequences after hospitalization for an acute cardiovascular event are not well established. We aimed to evaluate the prognostic impact of recreational drug use at 1-year follow-up on major adverse cardiovascular and cerebrovascular events (MACCE) in patients admitted to the ICCU. METHODS: The ADDICT-ICCU study (Addiction in Intensive Cardiac Care Units) is a prospective multicentric study including all consecutive patients admitted to the ICCU over 2 weeks in April 2021 at 39 French centers. Patients were excluded in cases of scheduled hospitalization, hospitalization within 24 hours before ICCU admission, or in-hospital death. Screening for recreational drug use was performed by a systematic urinary testing upon admission. The primary composite outcome was 1-year MACCE defined as cardiovascular death, nonfatal myocardial infarction, or stroke. Outcomes were adjudicated by 2 senior cardiologists after patient contact and review of anonymized records. A multivariable Cox regression analysis adjusted for traditional prognostic factors was performed to assess the independent association between overall recreational drug use and clinical outcomes. RESULTS: Of the 1392 patients assessed (63±15 years, 69.9% men), 157 (11.3%) had an initial positive test (cannabis or opioids, cocaine, amphetamines, or 3,4-methylenedioxymethamphetamine). After 1-year of follow-up, 94 (6.7%) patients experienced MACCE, with a higher incidence observed among drug users compared with nonusers (12.7% versus 6.0%; risk difference, 6.7% [95% CI, 1.5%–12.2%]). Cannabis or opioid use alone was also associated with MACCE (hazard ratio, 1.77 [95% CI, 1.02–3.08] for cannabis, and hazard ratio, 3.60 [95% CI, 1.57–8.23], for opioids). After adjustment for traditional prognostic factors, recreational drug use remained independently associated with MACCE (hazard ratio, 2.91 [95% CI, 1.68–5.05]). CONCLUSIONS: Recreational drug use markedly increases the risk of 1-year adverse cardiovascular outcomes in ICCU patients highlighting the need for targeted, tailored interventions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05063097.


  • Open Access

    Prognostic Impact of Recreational Drug Use on 1-Year Outcomes in NSTEMI and STEMI Patients

    by Michael Aboujaoude, Nefissa Hamache, Jean Guillaume Dillinger, Antonin Trimaille, Claire Bouleti, Clément Delmas, Guillaume Schurtz, Sonia Houssany-Pissot, Reza Rossanaly Vasram, Guillaume Bonnet, et al.


  • Comparative Prognostic Value of LGE in LV Dilatation With Preserved LVEF and Dilated Cardiomyopathy

    by Trecy Gonçalves, Théo Pezel, Suzanne Duhamel, Francesca Sanguineti, Philippe Garot, Alexandre Unger, Jean Guillaume Dillinger, Valérie Bousson, Solenn Toupin, Jérôme Garot

  • Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial

    by Jean-Guillaume Dillinger, Théo Pezel, Laure Batias, Denis Angoulvant, Marc Goralski, Emile Ferrari, Guillaume Cayla, Johanne Silvain, Martine Gilard, Gilles Lemesle, et al.

    Background and Aims: Despite current antithrombotic treatments, the recurrence of ischaemic events remains high in patients with diabetes mellitus (DM) or aspirin resistance after acute coronary syndrome (ACS). Whether twice-daily aspirin dosing reduces major adverse cardiovascular events (MACE) in this population remains unknown. Methods: In this prospective multicentre, randomized trial, patients with ACS and DM or high-risk of aspirin resistance (HRAR) defined as: (i) an index event occurring while on aspirin; (ii) body mass index ≥27 kg/m2; or (iii) increased waist circumference were assigned to receive enteric-coated aspirin once daily (100 mg/day) or twice daily (100 mg morning and evening). The primary outcome was MACE, a composite of any death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis, or acute arterial thrombotic event assessed using a time-to-first-event analysis. The main secondary outcome was major bleeding (Bleeding Academic Research Consortium type 3–5). Results: In total, 2484 participants were enrolled (77.2% with DM, 55.5% with ST-elevation segment myocardial infarction). The median follow-up duration was 18 (interquartile range: 17.6–18.3) months. The primary outcome occurred in 95 of 1228 participants (7.7%) in the twice-daily aspirin group, and 110 of 1256 (8.8%) in the once-daily group (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.69–1.19; P = .42). Major bleeding rates were similar between the groups (1.9% vs 2.1%; HR 0.88; 95% CI 0.50–1.55). Conclusions: In patients with ACS and DM or HRAR, twice-daily aspirin did not significantly reduce the risk of MACE compared to once-daily dosing. No significant difference was observed in major bleeding between groups. Trial Registration: NCT02520921/EUDRACT No: 2015-000947-18.